Study of PEP02 as a Second Line Therapy for Metastatic Pancreatic Cancer

Summary

The purpose of this study is to see the effect of PEP02 in the treatment of metastatic pancreatic cancer.

Timeline

Start

2009-01

Primary completion

2010-12

Completion

2012-07

Outcome

Met primary endpoint

paper The study met its primary end point with an OS(3-month) of 75% PMID 23880820 ↗

Publications

• Ko AH, Tempero MA, Shan YS, Su WC, Lin YL, Dito E, Ong A, Wang YW, Yeh CG, Chen LT. A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer. Br J Cancer. 2013 Aug 20;109(4):920-5. doi: 10.1038/bjc.2013.408. Epub 2013 Jul 23.

Drugs

Indications